natgillin/translations-raw huggingface dataset:
Prophylaxis should consist of adequate hydration and administration of uricostatics (e.g. allopurinol), or suitable alternative treatment such as urate oxidase (e.g. rasburicase), starting 12-24 hours prior to start of Gazyvaro infusion as per standard practice (see section 4.4). 
rasburikaza), ki se začne 12 do 24 ur pred začetkom dajanja infuzije zdravila Gazyvaro v skladu s standardno prakso (glejte poglavje 4.4).
IRRs 
Odmerek
Tumour lysis syndrome, hyperuricaemia, hypokalaemia 
Presnovne in prehranske motnje pogosti sindrom razpada tumorja, hiperurikemija, hipokaliemija sindrom razpada tumorja, hipokaliemija občasni hiperurikemija
Premedication to reduce the risk of IRRs is outlined in Table 1. 
Profilaksa reakcij, povezanih z infuzijo, in premedikacija zanje Premedikacija za zmanjšanje tveganja za reakcije, povezane z infuzijo, je prikazana v preglednici 1.
Less frequently reported: · irregular heartbeat · swelling of the throat or airway · wheezing, difficulty breathing, tight chest or throat irritation 
Psihiatrične motnje zelo pogosti nespečnost pogosti depresija, tesnoba občasni nespečnost, depresija, tesnoba
and the number of prior therapies (≤ 2 versus > 2). 
*Stratifikacijska dejavnika za analizo sta bila vrsta refraktarnosti (na monoterapijo z rituksimabom oz. na rituksimab + kemoterapijo) in število predhodnih zdravljenj (≤ 2 ali > 2).
Water for injections 
• okužba pljuč
No incompatibilities have been observed between Gazyvaro, in concentration ranges from 0.4 mg/mL to 20.0 mg/mL after dilution of Gazyvaro with sodium chloride 9 mg/mL (0.9%) solution for injection, and: · PVC, polyethylene (PE), polypropylene or polyolefin bags · PVC, polyurethane (PUR) or PE infusion sets · optional inline filters with product contact surfaces of polyethersulfone (PES), a 3-way stopcock infusion aid made from polycarbonate (PC), and catheters made from polyetherurethane (PEU). 
Inkompatibilnosti niso ugotovili med zdravilom Gazyvaro v razponu koncentracij od 0,4 mg/ml do 20,0 mg/ml po razredčenju z 0,9-% (9 mg/ml) raztopino natrijevega klorida za injekcije in:
* Chemotherapy: Chlorambucil in CLL; bendamustine, CHOP, CVP in iNHL including FL § observed also during maintenance treatment with at least 2% higher incidence in Gazyvaro arm (BO21223) 
• bolniki s predhodno nezdravljenim iNHL, ki so prejemali kombinacijo zdravila Gazyvaro in kemoterapije (bendamustin, CHOP, CVP), ki ji je pri odzivnih bolnikih sledilo vzdrževalno zdravljenje z zdravilom Gazyvaro, v primerjavi s kombinacijo rituksimaba in kemoterapije, ki ji je pri odzivnih bolnikih sledilo vzdrževalno zdravljenje z rituksimabom (študija BO21223/GALLIUM),
PHARMACEUTICAL FORM Concentrate for solution for infusion. 
Incidenca okužb je bila s kombinacijo zdravila
Histidine 
• driska
Gazyvaro was given by intravenous infusion as a dose of 1,000 mg on Days 1, 8 and 15 of Cycle 1, on Day 1 of Cycles 2-6, and in patients who did not have disease progression, once every two months for two years or until disease progression (whichever occurs first). 
nadaljujejo z monoterapijo z zdravilom Gazyvaro 1000 mg kot vzdrževalnim zdravljenjem enkrat na 2 meseca v obdobju 2 let ali do napredovanja bolezni (glede na to, kar se zgodi prej).
The recommended dose of Gazyvaro in combination with chlorambucil is 1,000 mg administered over Day 1 and Day 2 (or Day 1 continued), and on Day 8 and Day 15 of the first 28 day treatment cycle. 
1. in 2. dan (ali v nadaljevanju 1. dne) ter 8. in 15. dan prvega 28-dnevnega cikla zdravljenja.
Cycles 2-6 or 
2. do 6. ali
Diarrhoea, constipation§ 
Bolezni prebavil zelo pogosti diareja, zaprtost§
Hyperuricaemia 
Gazyvaro
NAME OF THE MEDICINAL PRODUCT Gazyvaro 1,000 mg concentrate for solution for infusion. 
Gazyvaro 1000 mg koncentrat za raztopino za infundiranje
Nasal congestion, rhinorrhoea, oropharyngeal pain 
• zvišana telesna temperatura, rdečica obraza ali mrzlica
Prophylaxis and premedication for tumour lysis syndrome (TLS) 
Premedikacija s kortikosteroidom je v prvem ciklu za bolnike s folikularnim limfomom (FL)
The recommended dose of Gazyvaro in combination with chlorambucil is 1,000 mg administered over Day 1 and Day 2, (or Day 1 continued), and on Day 8 and Day 15 of the first 28 day treatment cycle. 
Zdravilo Gazyvaro so dajali v obliki intravenske infuzije v odmerku 1000 mg 1., 8. in 15. dan 1. cikla zdravljenja in 1. dan nadaljnjih ciklov zdravljenja.
Most frequently reported: · nausea · fatigue · dizziness · headache · diarrhoea · fever, flushing or chills · vomiting · shortness of breath · low or high blood pressure · heart beating very fast · chest discomfort 
Bolezni krvi in limfatičnega sistema zelo pogosti nevtropenija§, trombocitopenija, anemija, levkopenija nevtropenija, trombocitopenija pogosti bolečina v bezgavki anemija, levkopenija
If the patient experienced an IRR during the previous infusion administer at 50 mg/hr. 
Če je imel bolnik med predhodnim infundiranjem reakcijo, povezano z infuzijo,
What benefit has Nespo shown during the studies? 
Kakšne koristi je zdravilo Nespo izkazalo med raziskavami?
Nespo exists in various strengths, from 10 to 500 micrograms per millilitre. 
Zdravilo Nespo je na voljo v različnih jakostih, od 10 do 500 mikrogramov na mililiter.
This summary was last updated in 09-2007.©EMEA 2007 
Povzetek je bil nazadnje posodobljen 09-2007.
Darbepoetin alfa is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes the cell able to produce darbepoetin alfa. 
Darbepoetin alfa je izdelan z metodo, imenovano „rekombinantna DNA tehnologija“: proizvede ga celica, ki je prejela gen (DNA), ki ji omogoča tvorbo darbepoetina alfa.
Nespo treatment should be initiated by a doctor who has experience in treating either of the two types of anaemia mentioned above. 
Zdravljenje z zdravilom Nespo mora uvesti zdravnik, ki ima izkušnje z zdravljenjem katere koli izmed zgoraj navedenih anemij.
The dose used depends on why Nespo is used, varying from 0.45 micrograms per kilogram every week (or 0.75 micrograms/kg every other week) in adults and children with kidney failure aged 11 years or older, to 6.75 micrograms/kg every three weeks in cancer patients. 
Uporabljeni odmerek je odvisen od namena uporabe zdravila Nespo in znaša od 0,45 mikrogramov na kilogram vsak teden (ali 0,75 mikrogramov/kg vsak drugi teden) pri ledvični odpovedi pri odraslih in otrocih, starih 11 let ali več, do 6,75 mikrogramov/kg vsake tri tedne pri bolnikih z rakom.
A lack of natural erythropoietin is also one of the causes of anaemia in patients receiving chemotherapy. 
Prav tako je pomanjkanje naravnega eritropoetina eden od vzrokov za anemijo pri bolnikih, ki prejemajo kemoterapijo.
The European Commission granted a marketing authorisation valid throughout the European Union for Nespo to Dompé Biotec S.p.A. on 8 June 2001. 
Evropska komisija je dovoljenje za promet z zdravilom Nespo, veljavno po vsej Evropski uniji, odobrila družbi Dompé Biotec S.p.A.
Nespo has also been studied in 124 children with long-term kidney disease to check that it is absorbed in the same way as in adults. 
Zdravilo Nespo so preučevali tudi pri 124 otrocih z dolgotrajnim ledvičnim obolenjem, kjer so ugotavljali, ali se absorbira na enak način kot pri odraslih.
Doses and dose frequency (how often Nespo is given) are adjusted depending on the response. 
Odmerki in frekvenca odmerjanja (pogostost uporabe zdravila Nespo) so prilagojeni odzivu organizma.
The marketing authorisation was renewed on 8 June 2006. 
dne 8. junija 2001.
• adults and children over one year of age with anaemia caused by long-term kidney failure, when the body does not produce enough of the natural hormone erythropoietin, 
• odraslih in otrocih, starih več kot eno leto, z anemijo, ki je nastala zaradi dolgotrajne ledvične odpovedi, kadar telo ne tvori dovolj naravnega hormona eritropoetina.
In all cases the doses are adjusted to obtain haemoglobin levels that remain within the recommended range. 
V vseh primerih so odmerki prilagojeni tako, da vzdržujejo koncentracijo hemoglobina v priporočljivih vrednostih.
The most common side effects with Nespo (seen in between 1 and 10 patients in 100) are headache, hypertension (high blood pressure), thrombosis (blood clots), injection site pain, arthralgia (joint pain) and peripheral oedema (fluid retention). 
Najpogostejši neželeni učinki zdravila Nespo (opaženi pri 1 do 10 bolnikih izmed 100) so glavobol, hipertenzija (visok krvni tlak), tromboza (krvni strdki), bolečina na mestu vboda, artralgija (bolečina v sklepih) in periferni edem (zastajanje tekočine).
• adult patients with certain types of cancer who are receiving chemotherapy (the medicines used to treat cancer), when the chemotherapy stops the bone marrow producing enough blood cells. 
• odraslih z določeno vrsto raka, ki prejemajo kemoterapijo (zdravila za zdravljenje raka), ko kemoterapija prepreči zadostno proizvodnjo krvnih celic v kostnem mozgu.
Nespo is injected intravenously (into a vein) or subcutaneously (under the skin). 
Zdravilo Nespo se vbrizga intravensko (v žilo) ali subkutano (pod kožo).
The effectiveness of Nespo has been studied in patients with long-term kidney disease, where it was compared with recombinant human erythropoietin in four studies involving over 1,200 patients, and in patients receiving chemotherapy for cancer such as lung cancer, myeloma or lymphoma, where it was compared with placebo (a dummy treatment) in two studies involving 669 patients. 
Učinek zdravila Nespo so preučevali pri bolnikih z dolgotrajnim ledvičnim obolenjem, kjer so ga v štirih študijah, ki so vključevale več kot 1200 bolnikov, primerjali z rekombinantnim humanim eritropoetinom, preučevali pa so ga tudi pri bolnikih, ki prejemajo kemoterapijo za zdravljenje raka, kot je rak na pljučih, mielom ali limfom, kjer so ga v dveh študijah, ki sta vključevali 669 bolnikov, primerjali s placebom (zdravilom brez zdravilne učinkovine).
The main measure of effectiveness in patients with kidney disease was the increase in haemoglobin. 
Glavno merilo učinkovitosti pri bolnikih z ledvičnim obolenjem je bil porast koncentracije hemoglobina.
In patients with long-term kidney failure, the main cause of their anaemia is a lack of natural erythropoietin. 
Pri bolnikih z dolgotrajno ledvično odpovedjo je glavni vzrok za anemijo pomanjkanje naravnega eritropoetina.
The Committee for Medicinal Products for Human Use (CHMP) decided that Nespo's benefits are greater than its risks for the treatment of anaemia associated with chronic renal failure in adults and paediatric patients, and of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Nespo pri zdravljenju anemije, povezane s kronično odpovedjo ledvic pri odraslih in pediatričnih bolnikih, in simptomatske anemije pri odraslih onkoloških bolnikih z nemieloidnimi malignomi, ki prejemajo kemoterapijo, večje od z njim povezanih tveganj.
Nespo should not be used in people who may be hypersensitive (allergic) to darbepoetin alfa or any of the other ingredients, or in patients who have poorly controlled high blood pressure. 
Zdravila Nespo se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) darbepoetin alfa ali na katerokoli drugo sestavino zdravila ali pri bolnikih s slabo nadzorovanim
Nespo is used to treat anaemia (fewer red blood cells in the blood than normal) in two groups of patients: 
Zdravilo Nespo se uporablja za zdravljenje anemije (v krvi je manj eritrocitov kot normalno) pri dveh
Nespo is supplied ready for use in a pre-filled syringe or pre-filled pen, which can be used by the patient or their carer. 
Zdravilo Nespo je na voljo za uporabo v napolnjeni injekcijski brizgi ali napolnjenem injekcijskem peresniku, ki ju lahko uporabi bolnik ali njegov negovalec.
How is Nespo used? 
Kako je bilo zdravilo Nespo raziskano?
Nespo works by stimulating the production of red blood cells in the same way as natural erythropoietin. 
Zdravilo Nespo deluje tako, da stimulira tvorbo eritrocitov na enak način kot naravni eritropoetin.
Lower doses may be necessary for children with kidney failure aged 10 years or below. 
Pri otrocih z ledvično odpovedjo, starih 10 let ali manj, bo morda potrebno uporabiti nižje odmerke.
The types of cancer where Nespo can be used are ‘non-myeloid' (do not affect the bone marrow). 
Zdravilo Nespo se lahko uporablja za „nemieloidne“ vrste rake (tiste, ki ne prizadenejo kostnega mozga).
In patients receiving chemotherapy, the main measure of effectiveness was the reduction in number of patients who needed a blood transfusion. 
Pri bolnikih, ki so prejemali kemoterapijo, je bilo glavno merilo učinkovitosti zmanjšanje števila bolnikov, ki so potrebovali
A hormone called erythropoietin stimulates the production of red blood cells from the bone marrow. 
Hormon, imenovan eritropoetin, stimulira sintezo eritrocitov v kostnem mozgu.
For the full list of all side effects reported with Nespo, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Nespo, glejte Navodilo za uporabo.
Nespo is a solution for injection in a vial, a pre-filled syringe or a pre-filled pen. 
Zdravilo Nespo je raztopina za injiciranje v viali, v napolnjeni injekcijski brizgi ali v napolnjenem injekcijskem peresniku.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NESPO EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) NESPO
See the Package Leaflet for full instructions for use. 
Za podrobnejša navodila o uporabi zdravila glejte Navodilo za uporabo.
In cancer patients receiving chemotherapy, fewer patients treated with Nespo needed a blood transfusion compared with those given placebo. 
Pri bolnikih z rakom, ki so prejemali kemoterapijo, je transfuzijo krvi potrebovalo manj bolnikov, zdravljenih z zdravilom Nespo, v primerjavi s tistimi
Darbepoetin alfa, the active substance in Nespo, acts exactly like the natural erythropoietin made by the body, but it is very slight different in its structure, and this means that darbepoetin alfa has a longer duration of action, and can be given less often than natural erythropoietin. 
vendar pa majhna razlika v njegovi strukturi pomeni, da darbepoetin alfa učinkuje dlje in se tako lahko daje manj pogosto kot naravni eritropoetin.
The full EPAR for Nespo is available here. 
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Nespo je na voljo tukaj.
Nespo was as effective as human recombinant erythropoietin at increasing the haemoglobin levels in patients with kidney disease, and at keeping these levels maintained after they had been improved, whether given as an intravenous or subcutaneous injection. 
Tako pri intravenskem kot pri subkutanem dajanju je bilo zdravilo Nespo pri zviševanju koncentracije hemoglobina pri bolnikih z obolenjem ledvic in pri ohranjanju dosežene koncentracije tako učinkovito kot humani rekombinantni eritropoetin.
How does Nespo work? 
Kako zdravilo Nespo deluje?
The Committee recommended that Nespo be given marketing authorisation. 
Odbor je zato je priporočil, da se za zdravilo Nespo
The medicine can only be obtained with a prescription. 
Zdravilo nima veā dovoljenja za promet
See the Package Leaflet for full details. 
Za več informacij glejte Navodilo za
Bialfar - Produtos Farmacêuticos, Sociedade Anónima 
Portugalska Bialfar - Produtos Farmacêuticos, Sociedade Anónima
Astrazeneca Produtos Farmacêuticos, Lda. 
Portugalska Astrazeneca Produtos Farmacêuticos, Lda.
Astrazeneca Produtos Farmaceuticos Limitada 
Portugalska Astrazeneca Produtos Farmaceuticos Limitada
Sandoz Hungária Kft 
Madžarska Sandoz Hungária Kft
Glaxo Wellcome Farmacêutica, Limitada 
Portugalska Glaxo Wellcome Farmacêutica, Limitada
Pentafarma - Sociedade TecnicoMedicinal S.A. 
Portugalska Pentafarma - Sociedade TecnicoMedicinal S.A.
Sandoz Farmacêutica, Limitada 
Portugalska Sandoz Farmacêutica, Limitada
Inhalation Powder, Hard Capsule 
Prašek za inhaliranje, trda kapsula
Astrazeneca Kft. 
Madžarska Astrazeneca Kft.
Montrose Kft 
Madžarska Montrose Kft
Clenil Compositum Beclometasone Dipropionate 0.8mg/2 Ml, Salbutamol Sulfate 1.928mg/2 Ml 
Clenil Compositum Beklometazon dipropionat 0,8 mg/2 ml, salbutamol sulfat 1,928 mg/2 ml
Pressurised Inhalation, Suspension 
Inhalacijska suspenzija pod tlakom
Budesonide 0.8mg Capsule 
Budezonid 0,8 mg kapsula
Salbutamol Sulfate 0.602mg Vial, Flunisolide 0.5mg Vial 
Salbutamol sulfat 0,602 mg viala, flunizolid 0,5 mg viala
Glaxosmithkline - Produtos Farmacêuticos, Limitada 
Portugalska Glaxosmithkline - Produtos Farmacêuticos, Limitada
Flunisolide 25mg Bottle, Salbutamol 10mg Bottle 
Flunizolid 25 mg steklenička, salbutamol 10 mg steklenička
Glaxosmithkline Kft. 
Madžarska Glaxosmithkline Kft.
Formoterol Fumarate Dihydrate 1,08 Mg, Beclometasone Dipropionate 18 Mg 
Formoterol fumarat dihidrat 1,08 mg, beklometazon dipropionat 18 mg
Budezonid Lek-Am Budesonide 200µg Inhalation 
Budezonid Lek-Am Budezonid 200 µg za inhaliranje
Samtoral Diskus Standard Fluticasone Propionate 250µg Dose, Salmeterol 50µg Dose 
Samtoral Diskus Standard Flutikazon propionat, odmerek 250 µg, salmeterol, odmerek 50 µg
Beclometason Ratiopharm Beclometasone Dipropionate 0.25mg/18.7g 
Beclometason Ratiopharm Beklometazon dipropionat 0,25 mg/18,7 g
Budosenide 320mcg, Formoterol Fumarate Dihydrate 9mcg 
Budozenid 320 mcg, formoterol fumarat dihidrat 9 mcg
Clenil Compositum Beclometasone Dipropionate 50µg Actuation, Salbutamol Sulfate 120µg Actuation 
Clenil Compositum Beklometazon dipropionat 50 µg s sprožitvijo, salbutamol sulfat 120 µg s sprožitvijo
Budezonid Lek-Am Budesonide 400µg Inhalation 
Budezonid Lek-Am Budezonid 400 µg za inhaliranje
Fluticasone Propionate 500 Microgram, Salmeterol Xinafoate 50 Microgram 
Flutikazon propionat 500 mikrogramov, salmeterol ksinafoat 50 mikrogramov
Budosenide 160mcg, Formoterol Fumarate Dihydrate 4.5mcg 
Budozenid 160 mcg, formoterol fumarat dihidrat 4,5 mcg
Belgium Orion Corporation 
Portugalska Orion Corporation
Beclometasone Dipropionate 250µg/59.2 Mg 
Beklometazon dipropionat 250 µg/59,2 mg
Fluticasone Propionate 0,5 Mg, Salmeterol Xinafoate 0,073 Mg 
Flutikazon propionat 0,5 mg, salmeterol ksinafoat 0,073 mg
Fluticasone Propionate 0,25 Mg, Salmeterol Xinafoate 0,073 Mg 
Flutikazon propionat 0,25 mg, salmeterol ksinafoat 0,073 mg
Salmeterol 25µg/Dose; Fluticasone Propionate 125µg/Dose 
Salmeterol 25 µg/odmerek; flutikazon propionat 125 µg/odmerek
Fluticasone Propionate 125µg Capsule Inhalation Powder, Hard Capsule 
Flutikazon propionat 125 µg kapsula Prašek za inhaliranje, trda kapsula
Netherlands Elpen Pharmaceutical Co. Inc. 
Nizozemska Elpen Pharmaceutical Co. Inc.
Budesonide 800µg Units 
Budezonid, enote po 800 µg
Beclometasone Dipropionate 50µg/59 Mg 
Beklometazon dipropionat 50 µg/59 mg
Fluticasone Propionate 100µg 
Flutikazon propionat 100 µg
Fluticasone Propionate 250µg Dose, Salmeterol 50µg Dose, Lactose Monohydrate 24.677mg Dose 
Flutikazon propionat, odmerek 250 µg, salmeterol, odmerek 50 µg, laktoza monohidrat, odmerek 24,677 mg
Fluticasone Propionate 250µg Capsule Inhalation Powder, Hard Capsule 
Flutikazon propionat 250µg kapsula Prašek za inhaliranje, trda kapsula
Budesonide 100µg Units 
Budezonid, enote po 100 µg
Beclometasone Dipropionate 250g/78mg 
Beklometazon dipropionat 250 g/78 mg
Fluticasone Propionate 500µg Dose, Salmeterol 50µg Dose, Lactose Monohydrate 24.677mg Dose 
Flutikazon propionat, odmerek 500 µg, salmeterol, odmerek 50 µg, laktoza monohidrat, odmerek 24,677 mg
Fluticasonpropionat „allen“ Fluticasone Propionate 250µg Dose Inhalation Powder 
Fluticasonpropionat „allen“ Flutikazon propionat, odmerek 250 µg Prašek za inhaliranje
Cyclocaps Beclometason Beclometasone Dipropionate 200µg Units 
Cyclocaps Beclometason Beklometazon dipropionat, enote po 200 µg
Fluticasone Propionate 125µg 
Flutikazon propionat 125 µg
Symbicort Mite Turbuhaler Budesonide 160µg Dose, Formoterol Fumarate Dihydrate 4.5µg Dose 
Symbicort Mite Turbuhaler Budezonid, odmerek 160 µg, formoterol fumarat dihidrat, odmerek 4,5 µg
Cyclocaps Beclometason Beclometasone Dipropionate 400µg Units 
Cyclocaps Beclometason Beklometazon dipropionat, enote po 400 µg
Fluticasone Propionate 500µg Inhalation, Salmeterol 50µg Inhalation 
Flutikazon propionat 500 µg za inhaliranje, salmeterol 50 µg za inhaliranje
Cyclocaps Beclometason Beclometasone Dipropionate 100µg Units 
Cyclocaps Beclometason Beklometazon dipropionat, enote po 100 µg
Fluticasone Propionate 250µg Inhalation, Salmeterol Xinafoate 25µg Inhalation 
Flutikazon propionat 250 µg za inhaliranje, salmeterol ksinafoat 25 µg za inhaliranje
Fluticasone Propionate 250µg 
Flutikazon propionat 250 µg
Budesonide 320µg Inhalation, Formoterol Fumarate Dihydrate 9µg Inhalation 
Budezonid 320 µg za inhaliranje, formoterol fumarat dihidrat 9 µg za inhaliranje
Symbicort Forte Turbohaler Budesonide 320µg Dose, Formoterol Fumarate Dihydrate 9µg Dose 
Symbicort Forte Turbohaler Budezonid, odmerek 320 µg, formoterol fumarat dihidrat, odmerek 9 µg
Fluticasone Propionate 50µg 
Flutikazon propionat 50 µg
Beclometasone Dipropionate 0,1 Mg Pressurised Inhalation, Solution 
Beklometazon dipropionat 0,1 mg Inhalacijska raztopina pod tlakom
Fluticasone Propionate 50µg Inhalation 
Flutikazon propionat 50 µg za inhaliranje
Budesonide 160µg Inhalation, Formoterol Fumarate Dihydrate 4.5µg Inhalation 
Budezonid 160 µg za inhaliranje, formoterol fumarat dihidrat 4,5 µg za inhaliranje
Symbicort Forte Turbuhaler Budesonide 320µg Dose, Formoterol Fumarate Dihydrate 9µg Dose 
Symbicort Forte Turbuhaler Budezonid, odmerek 320 µg, formoterol fumarat dihidrat, odmerek 9 µg
Fluticasonpropionat „allen“ Fluticasone Propionate 125µg Dose Pressurised Inhalation, 
Fluticasonpropionat „allen“ Flutikazon propionat, odmerek 125 µg Inhalacijska suspenzija pod tlakom
Budesonide, Micronised 0.4mg Actuation 
Budezonid, mikroniziran, 0,4 mg s sprožitvijo
Belgium Elpen Pharmaceutical Co. Inc. 
Madžarska Elpen Pharmaceutical Co. Inc.
Beclometasone Dipropionate 100g/18.7g 
Beklometazon dipropionat 100 g/18,7 g
Beclometasone Dipropionate 100µg Inhalation, Formoterol Fumarate 6µg Inhalation 
Beklometazon dipropionat 100 µg za inhaliranje, formoterol fumarat dihidrat 6 µg za inhaliranje
Fluticasone Propionate 100µg Dose Inhalation Powder 
Flutikazon propionat, odmerek 100 µg Prašek za inhaliranje
Fluticasone Propionate 250µg Inhalation 
Flutikazon propionat 250 µg za inhaliranje
Beclometasone Dipropionate 0.2mg Dose 
Beklometazon dipropionat, odmerek 0,2 mg
Fluticasonpropionat „allen“ Fluticasone Propionate 250µg Dose Pressurised Inhalation, 
Fluticasonpropionat „allen“ Flutikazon propionat, odmerek 250 µg Inhalacijska suspenzija pod tlakom
Fluticasone Propionate 125µg Inhalation 
Flutikazon propionat 125 µg za inhaliranje
Fluticasone Propionate 125µg Dose Aerosol 
Flutikazon propionat, odmerek 125 µg Aerosol
Beclometasone Dipropionate 0,2 Mg Pressurised Inhalation, Solution 
Beklometazon dipropionat 0,2 mg Inhalacijska raztopina pod tlakom
Fluticasone Propionate 250µg Dose Aerosol 
Flutikazon propionat, odmerek 250 µg Aerosol
Fluticasone Propionate 500µg Inhalation 
Flutikazon propionat 500 µg za inhaliranje
Budesonide 320µg Dose, Formoterol Fumarate Dihydrate Ph.Eur. 
Budezonid, odmerek 320 µg, formoterol fumarat dihidrat Ph.Eur., odmerek 9 µg
Budesonide, Micronised 200µg Dose Inhalation Powder 
Budezonid, mikroniziran, odmerek 200 µg
Fluticasone Propionate 250µg Dose Inhalation Powder 
Flutikazon propionat, odmerek 250 µg Prašek za inhaliranje
Budesonide 400µg Inhalation 
Budezonid 400 µg za inhaliranje
Budesonide, Micronised 0.2mg Actuation 
Budezonid, mikroniziran, 0,2 mg s sprožitvijo
Beclometasone Dipropionate 100µg Actuation, Formoterol Fumarate Dihydrate 6µg Dose 
Beklometazon dipropionat 100 µg s sprožitvijo, formoterol fumarat dihidrat, odmerek 6 µg
Salmeterol Xinafoate 50µg Dose, Fluticasone 250µg Dose 
Salmeterol ksinafoat, odmerek 50 µg, flutikazon, odmerek 250 µg
Budesonide 0.2mg Dose 
Budezonid, odmerek 0,2 mg
Formoterol Fumarate Dihydrate 6µg Dose, Beclometasone Dipropionate Anhydrous 100µg Dose 
Formoterol fumarat dihidrat 6 µg s sprožitvijo, brezvodni beklometazon dipropionat 100 µg s sprožitvijo